focus -WSS

focus

author：Wikipedia 2025-08-26 10:51:51 - browse：63354

A new treatment for Alzheimer’s disease developed by Eli Lilly slowed patients’ rate of cognitive and functional decline by 35% compared to placebo, the company said Wednesday, paving the way for a submission to the Food and Drug Administration and boosting hopes for a new class of Alzheimer’s drugs.

But the positive outcome of the study involving the drug, called donanemab, could be tempered by the deaths of two patients, and possibly a third, from a type of brain swelling caused by these drugs.

The results of the study were reported in a press release and have not yet been reviewed by outside scientists. Lilly said the data will be used to file for full approval with the FDA before the end of June. If cleared, donanemab will compete with another new Alzheimer’s treatment, Leqembi, made by Eisai and Biogen, that secured FDA approval in January.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Jerome Adams on the need for new antivirals for Covid
Next article： Doctor of U.S. President Joe Biden says he is fit for duty

Wikipedia

WSS

Children’s Hospital revives plan for pedestrian bridge

Covid overtakes 1918 Spanish flu as deadliest disease in U.S. history

Are embryos people? Reproductive medicine's future depends on the answer

Moonlake's readout produced a cash windfall. Risks remain

NEJM study measures Covid brain fog, impact on IQ

ChatGPT in medicine: STAT answers readers' burning questions

hotspot

focus

entertainment

Tori Bowie and the unacceptable rates of Black maternal death

Color Health wants to make cancer screenings convenient

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

Readout Newsletter: The latest on Amylyx, Moderna, Novavax

Jerome Adams on the need for new antivirals for Covid

Using force crossed my mind when examining a defiant young patient

The high cost of giving birth even with insurance

Neuroscience renaissance leads to new crop of psychiatric drugs

In age of alternative facts, a scholarly course on calling out crap

Affirmative action in medical school literally saved lives

explore

CDC advisory group OKs chikungunya vaccine

Apple is now the first public company to be valued at $3 trillion

What does generative AI mean for health care? We asked experts

Pfizer is about to make a big push in cancer. Will investors listen?

Ohio train derailment: Experts on toxic chemical risks

5 ways to address the shortage of health care workers

Wikipedia

focus

entertainment

hotspot